PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC

Detalles Bibliográficos
Autores principales: Lee, E., Matasar, M., Conlon, R., Mody, K., Fiset, S., Graff, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431702/
http://dx.doi.org/10.1097/01.HS9.0000851384.52638.ca
_version_ 1784780127844958208
author Lee, E.
Matasar, M.
Conlon, R.
Mody, K.
Fiset, S.
Graff, J.
author_facet Lee, E.
Matasar, M.
Conlon, R.
Mody, K.
Fiset, S.
Graff, J.
author_sort Lee, E.
collection PubMed
description
format Online
Article
Text
id pubmed-9431702
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94317022022-08-31 PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC Lee, E. Matasar, M. Conlon, R. Mody, K. Fiset, S. Graff, J. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431702/ http://dx.doi.org/10.1097/01.HS9.0000851384.52638.ca Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Lee, E.
Matasar, M.
Conlon, R.
Mody, K.
Fiset, S.
Graff, J.
PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC
title PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC
title_full PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC
title_fullStr PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC
title_full_unstemmed PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC
title_short PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC
title_sort pb2138: vitalize trial: a phase 2b, open-label, multicenter, randomized parallel-group, two-stage, study of maveropepimut-s, pembrolizumab, with or without intermittent low-dose cyclophosphamide, in r/r dlblc
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431702/
http://dx.doi.org/10.1097/01.HS9.0000851384.52638.ca
work_keys_str_mv AT leee pb2138vitalizetrialaphase2bopenlabelmulticenterrandomizedparallelgrouptwostagestudyofmaveropepimutspembrolizumabwithorwithoutintermittentlowdosecyclophosphamideinrrdlblc
AT matasarm pb2138vitalizetrialaphase2bopenlabelmulticenterrandomizedparallelgrouptwostagestudyofmaveropepimutspembrolizumabwithorwithoutintermittentlowdosecyclophosphamideinrrdlblc
AT conlonr pb2138vitalizetrialaphase2bopenlabelmulticenterrandomizedparallelgrouptwostagestudyofmaveropepimutspembrolizumabwithorwithoutintermittentlowdosecyclophosphamideinrrdlblc
AT modyk pb2138vitalizetrialaphase2bopenlabelmulticenterrandomizedparallelgrouptwostagestudyofmaveropepimutspembrolizumabwithorwithoutintermittentlowdosecyclophosphamideinrrdlblc
AT fisets pb2138vitalizetrialaphase2bopenlabelmulticenterrandomizedparallelgrouptwostagestudyofmaveropepimutspembrolizumabwithorwithoutintermittentlowdosecyclophosphamideinrrdlblc
AT graffj pb2138vitalizetrialaphase2bopenlabelmulticenterrandomizedparallelgrouptwostagestudyofmaveropepimutspembrolizumabwithorwithoutintermittentlowdosecyclophosphamideinrrdlblc

Ejemplares similares